Published in JAAPA on April 01, 2002
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A (2010) 1.38
Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother (2012) 0.99
Results of an antimicrobial control program at a university hospital. Am J Health Syst Pharm (2005) 0.93
Antiretroviral Regimen Durability and Success in Treatment-Naive and Treatment-Experienced Patients by Year of Treatment Initiation, United States, 1996-2011. J Acquir Immune Defic Syndr (2016) 0.87
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. J Clin Pharmacol (2014) 0.85
Focus Group Evaluation of the LIVE Network-An Audio Music Program to Promote ART Adherence Self-Management. Music Med (2012) 0.85
Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients. AIDS (2015) 0.84
Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. Clin Pharmacokinet (2014) 0.80
The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS (2016) 0.78
Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women. J Acquir Immune Defic Syndr (2015) 0.77
Issues in transfusion safety. JAAPA (2004) 0.75
Treatment of azole-resistant oropharyngeal candidiasis with topical amphotericin B. Ann Pharmacother (2002) 0.75
Avian influenza: what PAs need to know. JAAPA (2006) 0.75
Thoracic outlet syndrome. JAAPA (2005) 0.75
Late-onset drug fever associated with minocycline: case report and review of the literature. Pharmacotherapy (2003) 0.75
Avoiding overtransfusion: an update on risks and latest indications. JAAPA (2012) 0.75
Emerging infectious diseases and America's readiness. JAAPA (2002) 0.75
Head lice. Adv NPs PAs (2012) 0.75